Guo Kaidi, Li Li
Department of Gynecology and Oncology, Guangxi Medical University Cancer Hospital, Nanning, Guangxi, People's Republic of China.
Key Laboratory of Early Prevention and Treatment for Regional High Frequency Tumor, Ministry of Education, Nanning, Guangxi, People's Republic of China.
Int J Gen Med. 2021 Nov 16;14:8237-8248. doi: 10.2147/IJGM.S338044. eCollection 2021.
Ovarian cancer is one of the common malignant tumors of female reproductive organs, which seriously threatens the life and health of women. Resistance to chemotherapeutic drugs for ovarian cancer is the root cause of recurrence in most patients. The purpose of this study is to determine the differentially expressed genes of platinum resistance in ovarian cancer, and to screen out molecular targets and diagnostic markers that could be used to treat ovarian cancer platinum resistance.
We downloaded 5 gene microarray datasets GSE58470, GSE45553, GSE41499, GSE33482, and GSE15372 from the Gene Expression Omnibus database, all of which are associated with ovarian cancer platinum resistance. Subsequently, the intersection of the statistically significant differentially expressed genes in 5 gene chips was taken, and relevant bioinformatics and clinical parameters were performed on the screened differential genes. qRT-PCR was utilized to examine the mRNA expression levels in ovarian cancer sensitive and cisplatin-resistant cells.
Three differential genes, , may be closely related to platinum resistance of ovarian cancer, were screened by microarray datasets. According to the combined verification of bioinformatics, clinical case analyses and experiments, it was inferred that the increased expression of was beneficial to patients with platinum resistance, but the high expression of and may lead to the risk of platinum resistance.
and screened by relevant gene chips may serve as new biomarkers of platinum resistance in ovarian cancer.
卵巢癌是女性生殖器官常见的恶性肿瘤之一，严重威胁女性的生命健康。卵巢癌对化疗药物的耐药性是大多数患者复发的根本原因。本研究的目的是确定卵巢癌中铂耐药的差异表达基因，并筛选出可用于治疗卵巢癌铂耐药的分子靶点和诊断标志物。
我们从基因表达综合数据库下载了5个基因微阵列数据集GSE58470、GSE45553、GSE41499、GSE33482和GSE15372，所有这些数据集都与卵巢癌铂耐药相关。随后，取5个基因芯片中具有统计学意义的差异表达基因的交集，并对筛选出的差异基因进行相关生物信息学和临床参数分析。利用qRT-PCR检测卵巢癌敏感和顺铂耐药细胞中的mRNA表达水平。
通过微阵列数据集筛选出3个差异基因，可能与卵巢癌铂耐药密切相关。根据生物信息学、临床病例分析和实验的联合验证，推断基因的表达增加对铂耐药患者有益，但基因和的高表达可能导致铂耐药风险。
通过相关基因芯片筛选出的基因和可能作为卵巢癌铂耐药的新生物标志物。
